339 related articles for article (PubMed ID: 10732744)
1. Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy Working Party.
van Herpen CM; Jansen RL; Kruit WH; Hoekman K; Groenewegen G; Osanto S; De Mulder PH
Br J Cancer; 2000 Feb; 82(4):772-6. PubMed ID: 10732744
[TBL] [Abstract][Full Text] [Related]
2. Combination of interleukin-2 and interferon-alpha in renal cell carcinoma and malignant melanoma: a phase II clinical trial.
Veelken H; Rosenthal FM; Schneller F; von Schilling C; Guettler IC; Herrmann F; Mertelsmann R; Lindemann A
Biotechnol Ther; 1992; 3(1-2):1-14. PubMed ID: 1305889
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-2 with or without LAK cells in metastatic renal cell carcinoma: a report of a European multicentre study.
Negrier S; Philip T; Stoter G; Fossa SD; Janssen S; Iacone A; Cleton FS; Eremin O; Israel L; Jasmin C
Eur J Cancer Clin Oncol; 1989; 25 Suppl 3():S21-8. PubMed ID: 2697575
[TBL] [Abstract][Full Text] [Related]
4. Recombinant interferon-alpha 2a and vinblastine in advanced renal cell cancer: a clinical phase I-II study.
Kellokumpu-Lehtinen P; Nordman E
J Biol Response Mod; 1990 Aug; 9(4):439-44. PubMed ID: 2395008
[TBL] [Abstract][Full Text] [Related]
5. Concomitant administration of recombinant human interleukin-2 and recombinant interferon alfa-2A: an active outpatient regimen in metastatic renal cell carcinoma.
Figlin RA; Belldegrun A; Moldawer N; Zeffren J; deKernion J
J Clin Oncol; 1992 Mar; 10(3):414-21. PubMed ID: 1482425
[TBL] [Abstract][Full Text] [Related]
6. Phase I trial of recombinant interleukin-2 and recombinant beta-interferon in refractory neoplastic diseases.
Paolozzi F; Zamkoff K; Doyle M; Konrad M; Bradley EC; Rudolph A; Newman N; Gullo J; Scalzo A; Poiesz B
J Biol Response Mod; 1989 Apr; 8(2):122-39. PubMed ID: 2786553
[TBL] [Abstract][Full Text] [Related]
7. A phase 2 trial of recombinant interleukin-2 and 5-fluorouracil in patients with metastatic colorectal carcinoma.
Reid I; Sharpe I; Maxwell W; McDevitt J; Franks CR; Tanner WA; Monson JR
Eur J Surg Oncol; 1992 Dec; 18(6):591-8. PubMed ID: 1478292
[TBL] [Abstract][Full Text] [Related]
8. Recombinant interferon alpha-2 (INTRON A) in a phase II study of renal cell carcinoma.
Kempf RA; Grunberg SM; Daniels JR; Skinner DG; Venturi CL; Spiegel R; Neri R; Greiner JM; Rudnick S; Mitchell MS
J Biol Response Mod; 1986 Feb; 5(1):27-35. PubMed ID: 3958753
[TBL] [Abstract][Full Text] [Related]
9. Pretreatment natural killer antigen density correlates to clinical response in tumor patients receiving long-term subcutaneous recombinant interleukin-2 and recombinant interferon-alpha.
Duensing S; Hadam M; Körfer A; Schomburg A; Menzel T; Grosse J; Kirchner H; Poliwoda H; Atzpodien J
Mol Biother; 1992 Dec; 4(4):170-3. PubMed ID: 1282326
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of recombinant interferon alpha-C in patients with metastatic renal cell carcinoma.
Merimsky O; Inbar M; Merimsky E; Kovner F; Spitzer E; Laufer R; Braf Z; Chaitchik S
Mol Biother; 1990 Sep; 2(3):155-9. PubMed ID: 2222899
[TBL] [Abstract][Full Text] [Related]
11. [Combination therapy with natural type human tumor necrosis factor (MHR-24) and human lymphoblastoid interferon-alpha (MOR-22) against renal cell carcinoma--a multiclinic cooperative, early phase II study. Subcommittee on Urogenital Malignancy, Committee on MHR-24 against Tumors].
Niijima T; Akaza H; Koyanagi T; Togashi M; Kumamoto Y; Funyu T; Suzuki T; Orikasa S; Yoshikawa K; Koiso K
Hinyokika Kiyo; 1992 Oct; 38(10):1201-7. PubMed ID: 1481783
[TBL] [Abstract][Full Text] [Related]
12. Our experience with interferon alpha: renal cell carcinoma.
Merimsky O; Chaitchik S
Mol Biother; 1992 Sep; 4(3):130-4. PubMed ID: 1445666
[TBL] [Abstract][Full Text] [Related]
13. Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma.
Sznol M; Clark JW; Smith JW; Steis RG; Urba WJ; Rubinstein LV; VanderMolen LA; Janik J; Sharfman WH; Fenton RG
J Natl Cancer Inst; 1992 Jun; 84(12):929-37. PubMed ID: 1629914
[TBL] [Abstract][Full Text] [Related]
14. Treatment of renal cell carcinoma with alpha (human leukocyte) interferon and vinblastine in combination: a phase I-II trial.
Figlin RA; deKernion JB; Maldazys J; Sarna G
Cancer Treat Rep; 1985 Mar; 69(3):263-7. PubMed ID: 3978656
[TBL] [Abstract][Full Text] [Related]
15. [Treatment of advanced renal cell carcinoma with interferon alpha and OK-432 (streptococcal preparation)].
Shinoda M; Naide Y
Hinyokika Kiyo; 1992 Nov; 38(11):1299-304. PubMed ID: 1485585
[TBL] [Abstract][Full Text] [Related]
16. The results of a phase II randomized trial comparing 5-fluorouracil and 5-fluorouracil plus alpha-interferon: observations on the design of clinical trials for androgen-independent prostate cancer.
Daliani DD; Eisenberg PD; Weems J; Lord R; Fueger R; Logothetis CJ
J Urol; 1995 May; 153(5):1587-91. PubMed ID: 7536271
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of recombinant interferon alpha-2C in metastatic renal cell carcinoma.
Scheithauer W; Kuehrer I; Kutzmits R; Dittrich C; Steger G; Flener R; Ludwig H
J Biol Regul Homeost Agents; 1987; 1(2):81-6. PubMed ID: 3504086
[TBL] [Abstract][Full Text] [Related]
18. A phase II trial of interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma.
Ilson DH; Motzer RJ; Kradin RL; Vogelzang NJ; Bajorin DF; Scher HI; Nanus D; O'Moore P; Marathias K; Bosl GJ
J Clin Oncol; 1992 Jul; 10(7):1124-30. PubMed ID: 1607918
[TBL] [Abstract][Full Text] [Related]
19. Biochemotherapy of advanced metastatic renal-cell carcinoma: results of the combination of interleukin-2, alpha-interferon, 5-fluorouracil, vinblastine, and 13-cis-retinoic acid.
Atzpodien J; Kirchner H; Duensing S; Lopez Hänninen E; Franzke A; Buer J; Probst M; Anton P; Poliwoda H
World J Urol; 1995; 13(3):174-7. PubMed ID: 7550391
[TBL] [Abstract][Full Text] [Related]
20. Lonidamine versus high-dose tamoxifen in progressive, advanced renal cell carcinoma: results of an ongoing randomized phase II study.
Stahl M; Schmoll E; Becker H; Schlichter A; Hoffmann L; Wagner H; Possinger K; Müller W; Köllermann M; Weidenhammer W
Semin Oncol; 1991 Apr; 18(2 Suppl 4):33-7. PubMed ID: 2031196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
